Business Description
Andros Pharmaceuticals Co Ltd
ISIN : TW0006917008
Total Employee Number:
32Description
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 21.96 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.36 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 22.55 | |||||
Beneish M-Score | 20.46 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 33.9 | |||||
3-Year EBITDA Growth Rate | 0.2 | |||||
3-Year EPS without NRI Growth Rate | 3.2 | |||||
3-Year FCF Growth Rate | 1.6 | |||||
3-Year Book Growth Rate | 8.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 65.23 | |||||
9-Day RSI | 64.59 | |||||
14-Day RSI | 60.78 | |||||
3-1 Month Momentum % | -3.69 | |||||
6-1 Month Momentum % | 30.4 | |||||
12-1 Month Momentum % | 87.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 13.97 | |||||
Quick Ratio | 13.91 | |||||
Cash Ratio | 13.5 | |||||
Days Inventory | 109.01 | |||||
Days Sales Outstanding | 11.84 | |||||
Days Payable | 10.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.3 | |||||
Shareholder Yield % | -9.79 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 32.44 | |||||
Operating Margin % | -1363.3 | |||||
Net Margin % | -969.29 | |||||
EBITDA Margin % | -837.96 | |||||
FCF Margin % | -836.97 | |||||
OCF Margin % | -819.12 | |||||
ROE % | -12.73 | |||||
ROA % | -11.55 | |||||
ROIC % | -58.13 | |||||
3-Year ROIIC % | -24.56 | |||||
ROC (Joel Greenblatt) % | -218.54 | |||||
ROCE % | -12.08 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 289.92 | |||||
PB Ratio | 3.7 | |||||
Price-to-Tangible-Book | 3.7 | |||||
EV-to-EBIT | -29.17 | |||||
EV-to-EBITDA | -33.41 | |||||
EV-to-Revenue | 280.02 | |||||
EV-to-FCF | -28.63 | |||||
Price-to-GF-Value | 0.21 | |||||
| Price-to-Net-Current-Asset-Value | 5.61 | |||||
| Price-to-Net-Cash | 5.83 | |||||
Earnings Yield (Greenblatt) % | -3.42 | |||||
FCF Yield % | -2.44 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Andros Pharmaceuticals Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 5.548 | ||
| EPS (TTM) (NT$) | -1.16 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 0.06 | ||
| 3-Year Sortino Ratio | 0.14 | ||
| Volatility % | 87.73 | ||
| 14-Day RSI | 60.78 | ||
| 14-Day ATR (NT$) | 1.785527 | ||
| 20-Day SMA (NT$) | 31.7975 | ||
| 12-1 Month Momentum % | 87.75 | ||
| 52-Week Range (NT$) | 16.005502 - 45.95 | ||
| Shares Outstanding (Mil) | 55.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Andros Pharmaceuticals Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Andros Pharmaceuticals Co Ltd Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Andros Pharmaceuticals Co Ltd Frequently Asked Questions
What is Andros Pharmaceuticals Co Ltd(ROCO:6917)'s stock price today?
The current price of ROCO:6917 is NT$34.50. The 52 week high of ROCO:6917 is NT$45.95 and 52 week low is NT$16.01.
When is next earnings date of Andros Pharmaceuticals Co Ltd(ROCO:6917)?
The next earnings date of Andros Pharmaceuticals Co Ltd(ROCO:6917) is .
Does Andros Pharmaceuticals Co Ltd(ROCO:6917) pay dividends? If so, how much?
Andros Pharmaceuticals Co Ltd(ROCO:6917) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Andros Pharmaceuticals Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers